William M. Byra

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease

Faı̈ez Zannad, Stefan D. Anker, William M. Byra et al. · New England Journal of Medicine · 2018 · 336 citations · Full text

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Mandeep R. Mehra, Muthiah Vaduganathan, Min Fu et al. · European Heart Journal · 2019 · 95 citations · Full text

Rationale and Design of a Randomized, Double-Blind, Event-Driven, Multicentre Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Exacerbation of Heart Failure: The COMMANDER HF Trial

Faı̈ez Zannad, Barry Greenberg, John G.F. Cleland et al. · European Journal of Heart Failure · 2015 · 77 citations · Full text

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm

Barry Greenberg, James D. Neaton, Stefan D. Anker et al. · JAMA Cardiology · 2019 · 66 citations · Full text

Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction

Nicolas Girerd, John G.F. Cleland, Stefan D. Anker et al. · Scientific Reports · 2022 · 40 citations · Full text